BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer

NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Matt Wiley as Senior Vice President and Chief Commercial Officer (CCO).

“We are pleased to welcome Matt to our management team, as we prepare for our first potential approval and commercial launch of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “With over 25 years of commercial and industry expertise across multiple product launches including neuroscience products, Matt will be invaluable in spearheading critical launch initiatives, as well as the planned expansion of BXCL501 in additional indications, settings, and geographies, helping us maximize the potential of our AI-driven pipeline and R&D capabilities.”

Mr. Wiley brings a wealth of sales, marketing, and strategy experience across multiple specialty product launches. He joins BioXcel Therapeutics from VYNE Therapeutics, where he served as CCO overseeing all commercial objectives related to the launch of the company’s first two approved dermatology products, AMZEEQ and ZILXI. Prior to this, he served as Vice President of Marketing and Business Unit Lead for Jazz Pharmaceuticals’ sleep medicine unit, where he led the go-to-market strategy and marketing for SUNOSI for treating narcolepsy and sleep apnea and developed the successful growth strategy for XYREM for narcolepsy, which achieved $1.4 billion in net revenue during his final year. He also served as Vice President of Marketing at Azur Pharma, supporting the startup of U.S. operations and the company’s acquisition by Jazz Pharmaceuticals. In addition, Mr. Wiley held roles of increasing responsibility at Cephalon, Salix Pharmaceuticals, and MGI Pharma. He holds a BA in English from Syracuse University.

“I am thrilled to join BioXcel Therapeutics at such an important time, and I look forward to being part of efforts to bring BXCL501 to fill the unmet medical need for millions of patients managing acute agitation associated with schizophrenia and bipolar disorders,” said Mr. Wiley. “The Company’s AI-driven approach to drug development represents a novel way of identifying, developing and commercializing transformative neuroscience therapeutics, and I'm excited to join the leadership team in driving this innovative vision.”